ICOP

Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer

Retrieved on: 
Monday, August 1, 2022
Private Securities Litigation Reform Act, Patient, Pegfilgrastim, Doxorubicin, Hair loss, GLOBE, Drug, Innovation, Large-cell lung carcinoma, U.S. Securities and Exchange Commission, Research, TAC, PD, Incidence, Risk, Bias, Toxic leukoencephalopathy, ICOP, Therapy, Safety, Volunteering, Chemotherapy-induced peripheral neuropathy, Cancer, ALRN, Clinical trial, Filgrastim, Topotecan, NSCLC, Security (finance), Docetaxel, Nasdaq, Bone marrow, Serum, Breast cancer, Hair, Annual report, G-CSF, Induced cell cycle arrest, Cyclophosphamide, Form 10-K, Breast, Neutropenia, Squamous cell carcinoma, SCLC, Aileron, Coronavirus, Medical imaging, Pharmaceutical industry, Vaccine

Our team has worked methodically and expeditiously to modify the Phase 1b breast cancer trial in order to enhance our opportunity to demonstrate a robust chemoprotective effect of ALRN-6924 in patients with p53-mutated breast cancer.

Key Points: 
  • Our team has worked methodically and expeditiously to modify the Phase 1b breast cancer trial in order to enhance our opportunity to demonstrate a robust chemoprotective effect of ALRN-6924 in patients with p53-mutated breast cancer.
  • We expect that this will allow us to get to topline readouts for the breast cancer trial next year and if warranted by the trial results, to initiate preparation for a potential pivotal trial.
  • Five of the Sargon Research network sites, in addition to the Gabrail Cancer Center, will participate in the Aileron breast cancer trial.
  • Thus, the breast cancer trial will also enable the evaluation, across treatment cycles, of ALRN-6924s ability to prevent chemotherapy-induced alopecia.

Smithers Achieves Accreditation to Provide AS9120 Third-Party Certification Services

Retrieved on: 
Friday, June 3, 2022
Science, Time, Transport, Mark (given name), Aviation, CB, Accreditation, ICOP, Multimedia, CBS, MRO, Laboratory, Technology, Smithers, Boeing, Certification

AKRON, Ohio, June 3, 2022 /PRNewswire/ -- Smithers, a leading provider of testing, consulting, information, and compliance services, is pleased to announce the Smithers Quality Assessments Division has achieved accreditation by ANAB to offer AS9120 third-party certification services.

Key Points: 
  • AKRON, Ohio, June 3, 2022 /PRNewswire/ -- Smithers, a leading provider of testing, consulting, information, and compliance services, is pleased to announce the Smithers Quality Assessments Division has achieved accreditation by ANAB to offer AS9120 third-party certification services.
  • Accreditation to this standard will allow us to deliver our high touch certification services to both Maintenance Repair Operations (MRO) & distribution customers, and to better service our existing clients with the transition to AS9104/1A."
  • For more information about Smithers, AS9120 certification, please contact Mr. Aaron Dalby .
  • Founded in 1925 and headquartered in Akron, Ohio, Smithers is a multinational provider of testing, consulting, information, and compliance services.

Deep Lens and Southern Oncology Specialists Enter Strategic Partnership That Will Use AI-Based Solution VIPER™ to Improve Clinical Trial Matching

Retrieved on: 
Thursday, October 28, 2021
Data Management, Other Health, Technology, Pharmaceutical, Physical Therapy, Oncology, Managed Care, Hospitals, Clinical Trials, Science, Biotechnology, Software, Other Science, Health, Research, Research, Technology, Diagnosis, Cancer, Disease, Innovation, ICOP, Pathology, CLIA, Partnership, Patient, Helmy Eltoukhy, VIPER, Foundation Medicine, Time, Precision medicine, Clinical trial, EMR, Population, Deep Lens Survey, Tempus, Medical imaging, Southern Oncology Specialists, Deep Lens, SOUTHERN ONCOLOGY SPECIALISTS, DEEP LENS

Southern Oncology Specialists and Deep Lens today announced that they have entered into a strategic agreement that will use Deep Lens artificial intelligence (AI) based technology and other services to expand the practices clinical trial offering to patients.

Key Points: 
  • Southern Oncology Specialists and Deep Lens today announced that they have entered into a strategic agreement that will use Deep Lens artificial intelligence (AI) based technology and other services to expand the practices clinical trial offering to patients.
  • Southern Oncology Specialists offers comprehensive cancer care and serves patients in four locations in the greater Charlotte region.
  • Deep Lens is a digital healthcare company that uses AI to accelerate clinical trial recruitment and enrollment for community oncology practices.
  • The Deep Lens pre-screening and clinical trial matching solution is provided at no cost to oncology practices.

Janus Henderson Announces Decarbonisation Panel at World Climate Summit – Investment COP – at COP 26 in Glasgow

Retrieved on: 
Monday, October 25, 2021
Professional Services, Philanthropy, Fund Raising, Finance, Foundation, Banking, Janus, Â, Janus Henderson, 2016 United Nations Climate Change Conference, City, ICOP, Hearing, Policy, NYSE, Australian Securities Exchange, Investment, CISL, Conference, New, Climate change, ASX, CEO, COP26, Solution, JHG, Renewable energy

Janus Henderson Group plc (NYSE: JHG, ASX: JHG) announces it will host a panel event at the Investment COP (ICOP) summit in Glasgow.

Key Points: 
  • Janus Henderson Group plc (NYSE: JHG, ASX: JHG) announces it will host a panel event at the Investment COP (ICOP) summit in Glasgow.
  • The panel, entitled Is decarbonisation an opportunity for emerging markets?, will take place at 13:30 BST on Monday 8th November 2021 at the Glasgow Hilton Hotel.
  • The event will bring together experts from across the globe to discuss the opportunities and challenges that decarbonisation presents in the financial services sector across emerging markets.
  • The panel forms part of the World Climate Summits Investment COP, a leading forum for business and investment-driven solutions to climate change and a key side event to the United Nations Climate Change Conference (COP26) taking place in Glasgow from 1st - 12th November 2021.

Deep Lens and Ocala Oncology/Florida Cancer Affiliates Collaborate to Expand Clinical Research Program with AI-Based Trial Matching Solution

Retrieved on: 
Wednesday, October 20, 2021
Data Management, Other Health, Technology, Pharmaceutical, Practice Management, Oncology, Managed Care, Hospitals, Clinical Trials, Science, Biotechnology, Software, Other Science, Health, Research, Clinical trial, Innovation, EMR, MD, Hematology, Diagnosis, Pathology, Research, Foundation Medicine, Patient, Partnership, Deep Lens Survey, Population, Cancer, ICOP, VIPER, Helmy Eltoukhy, Medical imaging, Ocala Oncology/Florida Cancer Affiliates, Deep Lens, OCALA ONCOLOGY/FLORIDA CANCER AFFILIATES, DEEP LENS

Ocala Oncology/ Florida Cancer Affiliates and Deep Lens today announced that they have entered into a strategic agreement to expand the well-established clinical research program and offering to patients at the Ocala-based practice.

Key Points: 
  • Ocala Oncology/ Florida Cancer Affiliates and Deep Lens today announced that they have entered into a strategic agreement to expand the well-established clinical research program and offering to patients at the Ocala-based practice.
  • Ocala Oncology/Florida Cancer Affiliates specializes in hematology and oncology care and serves patients in the Central Florida area.
  • Deep Lens pre-screening and clinical trial matching solution is provided at no cost to oncology practices.
  • Deep Lens is a digital healthcare company focused on a groundbreaking approach to faster recruitment of the best-suited cancer patients to clinical trials.

The Smithers Quality Assessments Division Achieves Market Leading Position with Boeings Scorecard Results

Retrieved on: 
Tuesday, October 12, 2021
Technology, United States Air Force Tactical Air Control Party, CB, Industry, General manager, Attention, Marketing, Time, Audit, Transport, Certification, AS9100, Laboratory, Smithers, Network Rail Certification Body, ISO, Science, ICOP, CBS, Americas, Airline

AKRON, Ohio, Oct. 12, 2021 /PRNewswire/ -- Smithers, a leading provider of testing, consulting, information, and compliance services, is pleased to announce that the Smithers Quality Assessments Division has achieved a market leading position amongst Certification Bodies (CBs) with the most recently reported Boeing's CB Report Card.

Key Points: 
  • AKRON, Ohio, Oct. 12, 2021 /PRNewswire/ -- Smithers, a leading provider of testing, consulting, information, and compliance services, is pleased to announce that the Smithers Quality Assessments Division has achieved a market leading position amongst Certification Bodies (CBs) with the most recently reported Boeing's CB Report Card.
  • "Smithers Quality Assessments division has remained committed to working with our partners at Boeing to continually drive their important supplier performance inputs into our regular assessment activities.
  • We are proud of the commitment of our back office team, Auditors and Clients in helping us achieve these marketing leading results," says Aaron Troschinetz, General Manager, North America, Smithers Quality Assessments Division.
  • Jeanette Preston, President of Smithers Quality Assessments Division, also serves as the sole CB focal for the Americas Aerospace scheme.